Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock Rated “Moderate Buy” by Sell-Side Analysts

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) have earned an average rating of “Moderate Buy” from the twelve research firms that are covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation and ten have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $75.44.

Several equities research analysts recently commented on the company. Zacks Research downgraded Enliven Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 13th. Morgan Stanley assumed coverage on Enliven Therapeutics in a report on Friday, October 2nd. They issued an “overweight” rating and a $70.00 price target for the company. Guggenheim reaffirmed a “buy” rating on shares of Enliven Therapeutics in a research report on Thursday, October 8th. William Blair assumed coverage on shares of Enliven Therapeutics in a research note on Tuesday, August 18th. They set an “outperform” rating on the stock. Finally, Stifel Nicolaus lifted their price objective on shares of Enliven Therapeutics from $80.00 to $82.00 and gave the company a “buy” rating in a research note on Thursday, August 6th.

Enliven Therapeutics Trading Up 5.4%

Shares of NASDAQ ELVN opened at $47.25 on Thursday. Enliven Therapeutics has a 12-month low of $14.78 and a 12-month high of $62.32. The stock has a fifty day moving average price of $47.80 and a 200 day moving average price of $42.87.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). On average, equities analysts expect that Enliven Therapeutics will post -1.79 earnings per share for the current fiscal year.

Insider Activity at Enliven Therapeutics

In related news, Director J. Scott Garland sold 13,000 shares of Enliven Therapeutics stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $46.67, for a total value of $606,710.00. Following the completion of the sale, the director owned 13,000 shares in the company, valued at approximately $606,710. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Benjamin Hohl sold 6,018 shares of the company’s stock in a transaction on Monday, October 19th. The shares were sold at an average price of $38.48, for a total transaction of $231,572.64. Following the completion of the sale, the chief financial officer directly owned 38,000 shares in the company, valued at $1,462,240. This represents a 13.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 31,054 shares of company stock valued at $1,493,823. Company insiders own 3.00% of the company’s stock.

Hedge Funds Weigh In On Enliven Therapeutics

A number of hedge funds have recently bought and sold shares of ELVN. Pictet Asset Management Holding SA boosted its stake in Enliven Therapeutics by 14.1% in the third quarter. Pictet Asset Management Holding SA now owns 1,325,740 shares of the company’s stock valued at $60,772,000 after acquiring an additional 163,956 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Enliven Therapeutics during the third quarter valued at approximately $172,000. Profund Advisors LLC grew its holdings in shares of Enliven Therapeutics by 260.8% during the third quarter. Profund Advisors LLC now owns 27,874 shares of the company’s stock valued at $1,278,000 after purchasing an additional 20,148 shares during the last quarter. ProShare Advisors LLC raised its position in shares of Enliven Therapeutics by 29.5% during the 3rd quarter. ProShare Advisors LLC now owns 9,852 shares of the company’s stock worth $452,000 after purchasing an additional 2,246 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of Enliven Therapeutics by 37.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,369 shares of the company’s stock worth $622,000 after purchasing an additional 3,676 shares during the period. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer. The company uses small-molecule drug discovery and development to pursue treatments designed to address validated cancer targets and improve patient outcomes.

Enliven’s pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for the treatment of chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for use in patients with HER2-positive solid tumors.